Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Prednisone
Napp Pharmaceuticals Ltd
H02AB07
Prednisone
1mg
Modified-release tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06030200; GTIN: 5012854031159
PACKAGE LEAFLET : INFORMATION FOR THE USER _LODOTRA_® 1 MG, 2 MG AND 5 MG MODIFIED- RELEASE TABLETS PREDNISONE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What _LODOTRA _is and what it is used for 2. What you need to know before you take _LODOTRA_ 3. How to take _LODOTRA_ 4. Possible side effects 5. How to store _LODOTRA_ 6. Contents of the pack and other information 1. WHAT _LODOTRA _IS AND WHAT IT IS USED FOR _LODOTRA _is a tablet with a delayed release behaviour of the active compound prednisone, which is a corticosteroid. Corticosteroids have an anti-inflammatory action. Antiinflammatory medicines reduce pain, swelling, stiffness, redness and heat in affected joints. These tablets are used to treat: moderate to severe, active rheumatoid arthritis, particularly when accompanied by morning stiffness, in adults. These tablets are modified-release tablets. This means that they are designed to release prednisone approximately 4 hours after swallowing. This allows you to take _LODOTRA _at bedtime and feel an improvement in your early morning symptoms such as stiffness. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE _LODOTRA_ DO NOT TAKE _LODOTRA_ if you are allergic (hypersensitive) to prednisone or any of the other ingredients of these tablets (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking these tablets. TAKE SPECIAL CARE WITH _LODOTRA _ You must tell your doctor if you have (at the moment) or have had (in the past) any of the following conditio Read the complete document
OBJECT 1 LODOTRA 1 MG MODIFIED-RELEASE TABLETS Summary of Product Characteristics Updated 07-Mar-2018 | Napp Pharmaceuticals Limited 1. Name of the medicinal product _LODOTRA_ 1 mg modified-release tablets _LODOTRA_ 2 mg modified-release tablets _LODOTRA _5 mg modified-release tablets 2. Qualitative and quantitative composition _LODOTRA_ 1 mg: One modified-release tablet contains 1 mg of prednisone. _LODOTRA _2 mg: One modified-release tablet contains 2 mg of prednisone. _LODOTRA _5 mg: One modified-release tablet contains 5 mg of prednisone. Excipient with known effect: lactose _LODOTRA_ 1 mg: Each modified-release tablet contains 42.80 mg of lactose. _LODOTRA_ 2 mg: Each modified-release tablet contains 41.80 mg of lactose. _LODOTRA_ 5 mg: Each modified-release tablet contains 38.80 mg of lactose. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Modified-release tablet _LODOTRA_ 1 mg: Pale yellowish-white, cylindrical modified-release tablet, 5 mm in height and 9 mm in diameter, with “NP1” embossed on one side. _LODOTRA_ 2 mg: Yellowish-white, cylindrical modified-release tablet, 5 mm in height and 9 mm in diameter, with “NP2” embossed on one side. _LODOTRA _5 mg: Light yellow, cylindrical modified-release tablet, 5 mm in height and 9 mm in diameter, with “NP5” embossed on one side. 4. Clinical particulars 4.1 Therapeutic indications _LODOTRA_ is indicated for the treatment of moderate to severe, active rheumatoid arthritis, particularly when accompanied by morning stiffness, in adults. 4.2 Posology and method of administration Posology The appropriate dose depends on the severity of the condition and the individual response of the patient. In general, for the initiation of the therapy 10 mg prednisone is recommended. In certain cases, a higher initial dose might be required (e.g. 15 or 20 mg prednisone). Depending on the clinical symptoms and the patient's response, the initial dose can be reduced in steps to a lower maintenance dose. When changing over from the standard reg Read the complete document